Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Epidemiologic and genomewide association studies have linked loss-of-function variants in ANGPTL3, encoding angiopoietin-like 3, with low levels of plasma lipoproteins. METHODS: We evaluated antisense oligonucleotides (ASOs) targeting Angptl3 messenger RNA (mRNA) for effects on plasma lipid levels, triglyceride clearance, liver triglyceride content, insulin sensitivity, and atherosclerosis in mice. Subsequently, 44 human participants (with triglyceride levels of either 90 to 150 mg per deciliter [1.0 to 1.7 mmol per liter] or >150 mg per deciliter, depending on the dose group) were randomly assigned to receive subcutaneous injections of placebo or an antisense oligonucleotide targeting ANGPTL3 mRNA in a single dose (20, 40, or 80 mg) or multiple doses (10, 20, 40, or 60 mg per week for 6 weeks). The main end points were safety, side-effect profile, pharmacokinetic and pharmacodynamic measures, and changes in levels of lipids and lipoproteins. RESULTS: The treated mice had dose-dependent reductions in levels of hepatic Angptl3 mRNA, Angptl3 protein, triglycerides, and low-density lipoprotein (LDL) cholesterol, as well as reductions in liver triglyceride content and atherosclerosis progression and increases in insulin sensitivity. After 6 weeks of treatment, persons in the multiple-dose groups had reductions in levels of ANGPTL3 protein (reductions of 46.6 to 84.5% from baseline, P<0.01 for all doses vs. placebo) and in levels of triglycerides (reductions of 33.2 to 63.1%), LDL cholesterol (1.3 to 32.9%), very-low-density lipoprotein cholesterol (27.9 to 60.0%), non-high-density lipoprotein cholesterol (10.0 to 36.6%), apolipoprotein B (3.4 to 25.7%), and apolipoprotein C-III (18.9 to 58.8%). Three participants who received the antisense oligonucleotide and three who received placebo reported dizziness or headache. There were no serious adverse events. CONCLUSIONS: Oligonucleotides targeting mouse Angptl3 retarded the progression of atherosclerosis and reduced levels of atherogenic lipoproteins in mice. Use of the same strategy to target human ANGPTL3 reduced levels of atherogenic lipoproteins in humans. (Funded by Ionis Pharmaceuticals; ClinicalTrials.gov number, NCT02709850 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, the LDL-C lowering effects of ANGPTL3 inhibition with either monoclonal antibodies or antisense oligonucleotides seems to be LDL receptor (LDLR) independent since marked LDL-C lowering is observed in both Ldlr knock-out (KO) mice6,8 and patients with homozygous familial hypercholesterolemia (hoFH).9”
In the citing paper
“Interestingly, the LDL-C lowering effects of ANGPTL3 inhibition with either monoclonal antibodies or antisense oligonucleotides seems to be LDL receptor (LDLR) independent since marked LDL-C lowering is observed in both Ldlr knock-out (KO) mice6,8 and patients with homozygous familial hypercholesterolemia (hoFH).9”
In the citing paper
“A decrease in VLDL-TG secretion, but not in VLDL apoB secretion or VLDL clearance, was observed in mouse models treated with a monoclonal antibody6 or antisense oligonucleotides8 against ANGPTL3.”
In the citing paper
“In initial studies, treatment with Vupanorsen was associated with a 33%–63% decrease in triglycerides as well as reductions in Apo-C III, remnant and total cholesterol, HDL-C, and LDL-C (169).”
From Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8 (2021) · cites this paper as [169]
In the citing paper
“In a dose-finding study in HTG patients, IONIS-ANGPTL3-LRx reduced TG and LDL-C by up to 63.1% and 32.9%, respectively.82”
From Clinical review on triglycerides (2020) · cites this paper as [82]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585
Exome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia
Musunuru, K., Pirruccello, J. P., Do, R., Peloso, G. M., Guiducci, C., Sougnez, C., Garimella, K. V., Fisher, S., Abreu, J., Barry, A. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002926 · Cited by 754
Viney, N. J., van Capelleveen, J. C., Geary, R. S., Xia, S., Tami, J. A., Yu, R. Z., Marcovina, S. M., Hughes, S. G., Graham, M. J., Crooke, R. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31009-1 · Cited by 754
Self-citationAntisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528
Self-citationInactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
Dewey, F. E., Gusarova, V., O’Dushlaine, C., Gottesman, O., Trejos, J., Hunt, C., Van Hout, C. V., Habegger, L., Buckler, D., Lai, K.-M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510926 · Cited by 497
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease
Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507652 · Cited by 493
Targeting APOC3 in the familial chylomicronemia syndrome
Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400284 · Cited by 491
Self-citationWallace, C., Newhouse, S. J., Braund, P., Zhang, F., Tobin, M., Falchi, M., Ahmadi, K., Dobson, R. J., Marçano, A. C. B., Hajat, C., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2007.11.001 · Cited by 439
Research works printed but not linked: 1
- Romeo S, 2009, J Clin Invest, 119, 70
Cited by
Items 501–575 of 575
Aghasizadeh, M., Ahmadihoseini, A., Sahebi, R., Kazemi, T., Asadiyan‐Sohan, P., Esmaily, H., Samadi, S., Avan, A., Ferns, G. A., Bizhaem, S. K., et al. (2024) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.2418 · Cited by 1
Antisense Oligonucleotide Therapeutics Targeting Age-Related Diseases
Lee, H. G., Kim, J., Jang, C., & Shin, M. (2026) · BioDrugs · doi:10.1007/s40259-025-00761-x · Cited by 1
Krishnamurthy, S. S., Buzatto, A. Z., Campkin, C., Müller, H.-P., Wiesner, D., Weishaupt, J. H., Klose, V., Wiesenfarth, M., Elmas, Z., Herrmann, C., et al. (2026) · BMC Medicine · doi:10.1186/s12916-026-04749-4 · Cited by 2
Hou, Y., Luo, Y., Chen, J., Shang, X., Chang, Y., Zhang, X., Ding, Y., Zhao, W., Ding, C., Feng, X., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.07.036 · Cited by 1
Gamad, N., Shafiq, N., & Malhotra, S. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2019-136569 · Cited by 1
Wiggins, B. S. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001132 · Cited by 2
Muhammad, A. (2022) · International Journal of Clinical Cardiology · doi:10.23937/2378-2951/1410271 · Cited by 1
Lipid metabolism and the targeting of angiopoietin-like 3: Experimental drugs under development
Polychronopoulos, G., Kostourou, D.-T., & Τζιόμαλος, Κ. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2179480 · Cited by 1
Hypertriglyceridemia: diagnostic issues, therapeutic strategies
Bakaleiko, V. V., Reutova, O. V., Алиева, М. С., Baratashvili, G. G., Kostareva, A. A., & Alieva, A. S. (2024) · Russian Journal for Personalized Medicine · doi:10.18705/2782-3806-20244-3-194-205 · Cited by 1
Hughes, J. H., Amin, N. B., Wojciechowski, J., & Vourvahis, M. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13275 · Cited by 2
Zhang, H., Chen, W., Li, X., Song, Z., Liu, Y., Liu, S., Su, Z., Wu, W., Chen, H., Qin, C., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101514 · Cited by 2
Genetics and Genomics of Atherosclerotic Cardiovascular Disease
Musunuru, K., Qasim, A., & Reilly, M. P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812532-8.00007-0 · Cited by 4
Prospective Advances in Non-coding RNAs Investigation
Jan, M. I., Ali, T., Ishtiaq, A., Mushtaq, I., & Murtaza, I. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-1671-9_24 · Cited by 1
Low cholesterol syndrome and drug development
Handhle, A., Viljoen, A., Ramachandran, R., & Wierzbicki, A. S. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000745 · Cited by 3
Hypercholesterinämie - Wie erreiche ich ein LDL < 55 mg/dl?
Vogt, A. (2020) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-020-4373-0 · Cited by 1
Biologic therapy for dyslipidemia
Karásek, D. (2021) · Vnitřní lékařství · doi:10.36290/vnl.2021.054 · Cited by 2
Síndrome de Quilomicronemia Familiar: Algoritmo Diagnóstico
Colaco, I. B., Araújo, F., Aguiar, P., Cruz, D., Bourbon, M., Duarte, J. S., & Veríssimo, M. T. (2021) · Medicina Interna · doi:10.24950/rspmi.r.92.4.2021 · Cited by 1
Oshima, J., Hisama, F. M., & Martin, G. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812537-3.00015-9 · Cited by 1
Hou, G., Alissa, M., Alsuwat, M. A., Alarjany, H. M. A., Alzahrani, K. J., Althobaiti, F. M., Mujalli, H. M., Alotaiby, M. M., Al-Doaiss, A. A., & Anthony, S. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102627 · Cited by 1
Ангиопоэтиноподобный белок 3 типа – новая мишень гиполипидемической терапии
Помогайбо, Б. В., & Евгеньевич, Ф. А. (2022) · Атеросклероз и дислипидемии · doi:10.34687/2219-8202.jad.2022.02.0002 · Cited by 1
Lotta, L. A., Dong, L., Li, C., Patel, S., Stewart, I. D., Lim, K., Day, F. R., Wheeler, E., Glastonbury, C. A., de Streek, M. V., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/372128 · Cited by 2
Letter to the Editor: Is the HBsAg response to RO7062931 an antisense effect?
Vaillant, A. (2021) · Hepatology · doi:10.1002/hep.32103 · Cited by 1
Li, L., Chou, V. H. C., Chou, O. H. I., Roy, S., Chan, J. S. K., Wong, W. T., Liu, T., Lip, G. Y. H., Cheung, B. M. Y., Tse, G., et al. (2024) · medRxiv · doi:10.1101/2024.02.08.24302507 · Cited by 1
Widjaja, J. S., Adji, A. S., Baraja, A., Dharmasaputra, A., Rosyadi, R. N., Komalasari, I., Mustofa, A., Multazam, C. E. C. Z., Alkaff, F. F., & Saputra, P. B. T. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179420
Hypertriglyzeridämie und HDL-Mangel
von Eckardstein, A. (2017) · CardioVasc · doi:10.1007/s15027-017-1275-x
The year in cardiology 2017: prevention
Nordestgaard, B. G., Cosentino, F., Landmesser, U., & Laufs, U. (2018) · Cardiologia Croatica · doi:10.15836/ccar2018.79
Triglyceride and high density lipoprotein metabolism in diabetes
TOMKIN, G. H. (2018) · Journal of Diabetes Metabolic Disorders & Control · doi:10.15406/jdmdc.2018.05.00157 · Cited by 2
Antisense Technology: Liver Targeting and Beyond for Drug Discovery
Geary, R. S., Baker, B. F., & Monia, B. P. (2019) · Royal Society of Chemistry eBooks · doi:10.1039/9781788015714-00062 · Cited by 1
Self-citation4. Management of Disorders of Lipoprotein Metabolism-Update-
Ishibashi, S. (2018) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.107.453
Regulation of Lipoprotein Lipase Activity : an In-vitro Study of a Complex and Dynamic System
Kovrov, O. (2019) · DiVA at Umeå University (Umeå University)
Novel therapeutics in hypertriglyceridaemia and chylomicronaemia
García-Díaz, J. D. D. (2020) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2019.11.004
Universal cholesterol screening of youth—Are pediatric lipidologists smarter than a fifth grader?
Kohn, B., & Wilson, D. P. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.09.007
Emerging Therapies for Regulating Dyslipidaemias and Atherosclerosis
Ward, N. C., & Watts, G. F. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_33
Emerging New Lipid-Lowering Therapies in the Statin Era
Jang, A. Y., Jo, S., & Koh, K. K. (2021) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2021.1.e5
Transport of statins by human ABC efflux transporters in vitro
Tuomi, S.-K. (2021) · UTUPub (University of Turku)
Dislipidemias: terapêutica atual e perspectivas futuras na redução de riscos cardiovasculares
Lopes, M. G., & Sposito, A. C. (2018) · Revista Paulista de Reumatologia · doi:10.46833/reumatologiasp.2018.17.3.19-23
Novel APOB mutation in familial hypobetalipoproteinemia
Doménech, M., Llano‐Rivas, I., Arroyo, V., & Ortega, E. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.11.003
Medikamentöse Therapie der Fettstoffwechselstörungen im Kindesalter
Schwab, K. O., & Doerfer, J. (2022) · Springer eBooks · doi:10.1007/978-3-662-63320-5_5
Triglyceride-Rich Lipoproteins
Bazarbashi, N., & Miller, M. J. (2022) · Contemporary cardiology · doi:10.1007/978-3-030-98824-1_12
Klose, G., Gouni‐Berthold, I., & März, W. (2022) · Journal für Klinische Endokrinologie und Stoffwechsel · doi:10.1007/s41969-022-00178-9
Advanced therapeutics for targeting atherosclerosis
Bhunia, S. S., & Debnath, U. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99988-5.00005-x
Park, J. K., Bafna, S., Forrest, I. S., Duffy, Á., Márquez‐Luna, C., Petrazzini, B. O., Vy, H. M. T., Jordan, D. M., Verbanck, M., Narula, J., et al. (2023) · eLife · doi:10.7554/elife.80560.sa2
Overview of Lipids and Atherosclerosis
Libby, P. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00001-7 · Cited by 1
Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes
Bobik, A., Cohen, N. D., Jenkins, A. J., Kyaw, T. S., SULLIVAN, D. R., Wu, X., Yu, X.-Y., & Little, P. J. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_30
Farmakoterapi Pasien Hiperkolesterolemia Familial: Suatu Tinjauan Narasi
Laksono, S., & Afiyani, N. (2023) · Farmasains Jurnal Ilmiah Ilmu Kefarmasian · doi:10.22236/farmasains.v10i1.8743 · Cited by 1
Aghasizadeh, M., Ghanei, M., Ghoflchi, S., Asadiyan‐Sohan, P., Haghani, M., Kazemi, T., Esmaily, H., Avan, A., Ferns, G. A., Miri‐Moghaddam, E., et al. (2023) · Biochemical Genetics · doi:10.1007/s10528-023-10533-3
RNA interference-based therapies for atherosclerosis: Recent advances and future prospects
Parsamanesh, N., Poudineh, M., Siami, H., Butler, A. E., Almahmeed, W. A., & Sahebkar, A. (2023) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.12.009 · Cited by 3
Ischaemic Heart Disease in Diabetes
Lehrke, M., & Marx, N. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch49
Larouche, M., & Gaudet, D. (2024) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2024.01.009
Bai, J., Dong, Z., Zhang, L., Li, S., Chen, R., Di, J., Wang, W., Wu, Y., & Zhou, Y. (2024) · Research Square · doi:10.21203/rs.3.rs-4367440/v1
Brandts, J. (2024) · CardioVasc · doi:10.1007/s15027-024-3575-2
Exploring emerging pharmacotherapies for type 2 diabetes patients with hypertriglyceridemia
Tomlinson, B., & Chan, P. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2451752 · Cited by 2
Outland, E. H., Xin, Y., Dickson, A. L., Mundo, S., Tao, R., Zhong, X. Y., Karakoc, G., Serley, S., Jiang, L., Cox, N. J., et al. (2025) · medRxiv · doi:10.1101/2025.03.07.25323588 · Cited by 1
Delivery of Nucleic Acids for Vascular Tissue Engineering Applications
Wyse, J. M., Lopez, P., Miserlis, D., Koutakis, P., & Wechsler, M. E. (2025) · Regenerative Engineering and Translational Medicine · doi:10.1007/s40883-025-00421-0
Galatius, E. S., Lassen, M. C. H., Skaarup, K. G., Johansen, N. D., Galatius, S., Jensen, G. B., Schnohr, P., Møgelvang, R., & Biering‐Sørensen, T. (2025) · Echocardiography · doi:10.1111/echo.70249
Zhang, S., Zhao, J., Xie, X., Li, L., Chen, J., Liu, H., & Wang, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00732
Ghosh, J., Das, L., Lamba, D. S., Arjunan, D., Hans, R., Sharma, R. R., & Bhadada, S. K. (2025) · IJEM Case Reports · doi:10.4103/ijemcr.ijemcr_6_25
Von Kräutern zu Pillen, Biologics und Nukleinsäuren
Lüscher, T. F., von Eckardstein, A., Beer, J. H., Räber, L., Sudano, I., Nanchen, D., Mueller, C. E., Mach, F., & Landmesser, U. (2022) · Cardiovascular Medicine · doi:10.4414/cvm.2022.02258
Zuo, Y., Zhang, C., Zhou, Y., Li, H., Xiao, W., Herzog, R. W., Xu, J., Zhang, J., Chen, Y. E., & Han, R. (2023) · Figshare · doi:10.6084/m9.figshare.23529236
Huang, K. C., Yin, S., Xiao, Y., Wang, J., Cui, J., Wang, J., & Bai, Y. (2024) · Figshare · doi:10.6084/m9.figshare.25271926
Huang, K., Yin, S., Xiao, Y., Wang, J., Cui, J., Wang, J., & Bai, Y. (2024) · Figshare · doi:10.6084/m9.figshare.25271884
Foss-freitas, M. C., Akıncı, B., Neidert, A., Bartlett, V. J., Hurh, E., Karwatowska‐Prokopczuk, E., & Oral, E. A. (2021) · Figshare · doi:10.6084/m9.figshare.17127352
Self-citationIitake, C., Masuda, D., Koseki, M., & Yamashita, S. (2020) · Figshare · doi:10.6084/m9.figshare.13297272
Hu, X., Fan, J., Ma, Q., Han, L., Cao, Z., Xu, C., Luan, J., Jing, G., Nan, Y., Wu, T., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19801441
HDL and Cardiovascular Disease: Mechanisms, Therapeutic Advances, and Challenges
Sen, K., & Sinha, A. (2026) · Proceedings of the Zoological Society · doi:10.1007/s12595-026-00609-4
Zhang, X., Han, Y., Zheng, L., He, X., Pu, Y., Wei, L., Wang, Y., & Xian, X. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-02916-3
Mustafa, A., Irfan, T., Babar, M. M., & Rajadas, J. (2026) · Springer eBooks · doi:10.1007/978-981-95-3957-4_24
Current diabetes drugs: Lessons learned and implications for next-generation therapeutics
Liao, J., Cong, Z., Liu, K., Que, H., & Liu, F. (2026) · The Innovation Drug Discovery · doi:10.59717/j.xinn-drugdisc.2026.100008
Duan, Y., Gong, K., & Wang, D. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34186-1.01002-1
Adipokine in Metabolic Liver Disease: Adipo–Brain–Liver Cross talk
苏喻乐, Yang, Y., Sun, W., Yu, Z., Wang, Y., 刘世新, Chen, Z., Li, Y., Yang, X., Liu, J., et al. (2026) · International Journal of Endocrinology · doi:10.1155/ije/9009628
From particle count to residence time: a kinetic framework for atherogenic risk
Larronde, E. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1898635
Foia, L. G., Goriuc, A., Luchian, I. A., Budală, D. G., Toma, V., Bogdán, M., Minea, B., & Ghemiș, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177917
Zhao, R., Zheng, J.-L., Wang, Y., Lu, B., Zhang, Y., & Deng, B.-C. (2026) · World Journal of Hepatology · doi:10.4254/wjh.124748
Development of Antisense Oligonucleotide Gapmers for the Treatment of Dyslipidemia and Lipodystrophy
Aslesh, T., & Yokota, T. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5476-7_5
In vivo overexpression of ANGPTL3 promotes hepatic steatosis and inflammatory injury in chickens
Huang, L., Yan, P., Xiao, N., Liang, J., Zhao, Y., Zhao, L., Wang, J., Liu, J., Lu, H., Han, R., et al. (2026) · Veterinary Pathology · doi:10.1177/03009858261492643
Metadata
- Authors
- Graham, M. J., Lee, R. G., Brandt, T. A., Tai, L.-J., Fu, W., Peralta, R., Yu, R., Hurh, E., Paz, E., McEvoy, B. W., Baker, B. F., Pham, N. C., Digenio, A., Hughes, S. G., Geary, R. S., Witztum, J. L., Crooke, R. M., & Tsimikas, S.
- Affiliations
- Ionis Pharmaceuticals (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-07-20
- Volume
- 377
- Issue
- 3
- Pages
- 222-232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2618984243
- Cited by
- 573
- References
- 23
- Citations by year
- 2026: 20 · 2025: 36 · 2024: 48 · 2023: 51 · 2022: 85 · 2021: 86 · 2020: 90 · 2019: 59 · 2018: 72 · 2017: 26
- FWCI
- 52.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- ANGPTL3, antisense oligonucleotides, triglyceride lowering, hypertriglyceridemia, LDL cholesterol, hepatic triglyceride content, atherosclerosis, insulin sensitivity, lipoproteins, apolipoprotein B, apolipoprotein C-III, loss-of-function mutations, pharmacokinetics
- MeSH terms
- Angiopoietin-like Proteins, Angiopoietin-Like Protein 3, Adult, Aged, Animals, Coronary Artery Disease, Disease Models, Animal, Double-Blind Method, Female, Humans, Lipids, Male, Mice, Inbred Strains, Middle Aged, Oligonucleotides, RNA, Messenger, Oligonucleotides, Antisense, Angiopoietins, Dyslipidemias, Atherosclerosis, Lipid Metabolism, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.